Organigram Holdings (TSXV:OGI; OTCQB:OGRMF) announced the addition of a pure CBD edible oil product to their lineup of offerings.
As quoted in the press release:

This pure CBD product is a first for Organigram, complementing the company’s existing line of medical cannabis oil products.
Cannabinoids are the chemical compounds unique to cannabis that act upon the human body’s cannabinoid receptors. There are over 80 known cannabinoids present in the cannabis plant, each with varying effects. CBD (or Cannabidiol) is the second most prevalent cannabinoid in cannabis. Research has shown that CBD provides a therapeutic or calming effect without contributing to the “high” associated with Tetrahydrocannabinol (or THC), the psychoactive compound in cannabis.
“Patients are unique and require different products that help in different ways” says Greg Engel, CEO, Organigram. “As a result, we recognize the need to continually innovate and enhance both our processes and products. Today we are proud to extend our product offering and introduce Shubie Cannabis Oil as an option for patients who will benefit from its pure CBD formulation.”


Click here to read the full press release.

Source: www.marketwired.com

Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the ongoing U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

“We would like to welcome Dr. Moody as a medical and clinical advisor to our team and we look forward to his contributions in our ongoing FDA Phase 3 clinical study as well as expanding our COVID-19 studies in Canada,” said Michael Frank, CEO of Revive. “Dr. Moody’s experience in clinical epidemiology, data analysis and research are key to our FDA Phase 3 study as we gather clinical data from patients enrolled.”

Keep reading... Show less

– FinCanna Capital Corp. (CSE:CALI) (OTCQB:FNNZF), based in Vancouver, BC today announced that Andriyko Herchak, CEO, will present live at VirtualInvestorConferences.com on December 3 rd .

Keep reading... Show less

First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support patients with posttraumatic stress disorder

Keep reading... Show less

Multi-year partnership designates BioSteel as new official sports drink of Philadelphia 76ers team, Training Complex, and the presenting partner of 76ers Training Camp

BioSteel today announced a multi-year deal with the Philadelphia 76ers, making the sports hydration company the official sports drink of the team. BioSteel will also serve as a partner of the Philadelphia 76ers Training Complex, and the presenting partner for 76ers Training Camp, which begins next week.

Keep reading... Show less

Achievements with Scalability and Compatibility Pave Way for Next Phase of Advancement

Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) is excited to announce that the Company’s holding, Arcology, a cluster-computing powered AI blockchain ecosystem with unlimited scalability, has updated its working roadmap in response to its Testnet 1.0 results

Keep reading... Show less